Key result
Polypharmacy linked to higher bleeding risk in elderly AF patients on DOACs.
Why the study?
How to manage polypharmacy and its associated bleeding risks in elderly patients with non-valvular atrial fibrillation receiving DOACs remains an unmet clinical need.
Polypharmacy in elderly patients with non-valvular atrial fibrillation increases bleeding risk during DOAC therapy, highlighting an unmet clinical need for careful medication management.
Answers are grounded in this paper and cite their sources.
Should not yet change DOAC practice in polypharmacy elderly; leaves open prospective trials on risk mitigation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2020) conducted a review in Non-valvular atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Warfarin or no treatment was evaluated. Polypharmacy in elderly patients with non-valvular atrial fibrillation increases bleeding risk during direct oral anticoagulant therapy, necessitating careful monitoring and medication review.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: